Year 2022 / Volume 114 / Number 1
Original
Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study

10-15

DOI: 10.17235/reed.2021.7683/2020

Rocío Ferreiro-Iglesias, Manuel Barreiro-de Acosta, Javier López-Díaz, Iria Bastón Rey, Juan Enrique Domínguez-Muñoz,

Abstract
Background: monocytes play an important role in the pathogenesis of inflammatory bowel disease but data are scarce regarding activity biomarkers, above all in patients under biologic therapies. Objective: the aim of this study was to evaluate the value of monocyte measurements in predicting flares in inflammatory bowel disease patients under maintenance treatment with anti-TNF. Methods: a prospective, observational cohort study was designed. Relapse was defined as a Harvey-Bradshaw score > 4 in Crohn’s disease, and a partial Mayo score ≥ 2 in ulcerative colitis. Monocyte concentration was quantified at 4-month intervals for twelve months. A total of 95 consecutive patients were included. Median age was 42 years, 50.5 % were female, and 75 % had Crohn’s disease. Results: sixteen months after inclusion, 65 (68.4 %) patients remained in clinical remission. Mean monocyte count preceding a relapse was 563 (standard deviation: 144) compared to 405 (standard deviation: 177) in patients who remained in remission. Final monocyte count was significantly different between relapse and remission in Crohn’s disease (0.82; 95 % CI: 0.71-0.90; p < 0.005). According to the multivariate analysis, only monocytes and fecal calprotectin were related to more relapses. Conclusion: in conclusion, in inflammatory bowel disease patients under anti-TNF therapy, repeat monocyte counts could help monitor patients, at least in Crohn’s disease.
Share Button
New comment
Comments
No comments for this article
References
1. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55(3):426-31. DOI: 10.1136/gut.2005.069476
2. Gisbert JP, González Lama Y, Maté J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol 2007;30(3):117-29. DOI: 10.1157/13100073
3. Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009;2:221.
4. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60.
5. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early stage Crohn’s disease. Gastroenterology 2010;138:463-8.
6. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201.
7. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661-5.
8. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective longitudinal study. Gut 2008;57:1518-23.
9. Oyaert M, Boel A, Jacobs J, et al. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med 2017;55:1564-73.
10. Labaere D, Smismans A, Van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J 2014;2:30-7.
11. Coorevits L, Baert FJ, Vanpoucke HJ. Fecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med 2013;51:825-31.
12. Mee AS, Berney J, Jewell DP. Monocytes in inflammatory bowel disease: absolute monocyte counts. J Clin Pathol 1980;33:917-20.
13. Zhou L, Braat H, Faber KN, et al. Monocytes and their pathophysiological role in Crohn’s disease. Cell Mol Life Sci 2009;66:192-202.
14. Thayer WR Jr, Charland C, Field CE. The subpopulations of circulating white blood cells in inflammatory bowel disease. Gastroenterology 1976;71:379-84.
15. Jakubzick C, Gautier EL, Gibbings SL, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 2013;39:599-610.
16. Cherfane C, Anderson AJ, Ramos Rivers C, et al. Is monocytosis a biomarker of severity in inflammatory bowel disease? Analysis of a 6 year, prospective natural history registry. Gastroenterology 2016;150(4):S42. DOI: 10.1016/S0016-5085(16)30266-9
17. Cherfane C, Gessel L, Dominic C, et al. Monocytosis and a low lymphocyte to monocyte ratio are effective biomarkers of ulcerative colitis disease activity. Inflamm Bowel Dis 2015;21:1769-75.
18. Silverberg MS, Satsangi J, Ahmad T, et al. Towards an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of gastroenterology. Can J Gastroenterol 2005;19(suppl A):5A-36A. DOI: 10.1155/2005/269076
19. Mee AS, Berney J, Jewell DP. Monocytes in inflammatory bowel disease: absolute monocyte counts. J Clin Pathol 1980;33:917-20.
20. Zhou L, Braat H, Faber KN, et al. Monocytes and their pathophysiological role in Crohn’s disease. Cell Mol Life Sci 2009;66:192-202.
21. La Manna MP, Orlando V, Dieli F, et al. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. Plos One 2017;12(2):e0171358. DOI: 10.1371/journal.pone.0171358
22. Wei XB, Chen F, Huang JL, et al. Novel risk biomarker for infective endocarditis patients with normal ventricular ejection fraction – monocyte to high density lipoprotein colesterol ratio. Cir J 2007;82:283-8.
23. Woollard KJ, Geissman F. Monocytes in aterosclerosis: subsets and functions. Nat Rev Cardiol 2010;7:77-86.
24. Dutta P, Nahrendorf M. Monocytes in myocardial infarction. Arterioscler Thromb Vasc Biol 2015;35:1066-70.
25. Klimek E, Mikolajcyk T, Sulicka J, et al. Blood monocyte subsets and selected cardiovascular risk markers in rheumatoid arthritis of short duration in relation to disease activity. Biomed Res Int 2014;2014:736853.
26. Hensel M, Grädel L, Kutz A, et al. Peripheral monocytosis as a predictive factor for adverse outcome in the emergency department. Medicine 2017;96:e7404. DOI: 10.1097/MD.0000000000007404
27. García-Sánchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis 2010;4(2):144-52. DOI: 10.1016/j.crohns.2009.09.008
28. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflam- matory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8.
29. Lobatón T, López-García A, Rodríguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis 2013;7:641-51.
30. Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 2013;19:1034-42.
31. Ferreiro-Iglesias R, Barreiro-de Acosta M, Lorenzo A, et al. Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy. J Clin Gastroenterol 2016;50:147-51.
32. Ferreiro Iglesias R, Barreiro de Acosta M, Lorenzo Gonzalez A, et al. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn’s disease patients on maintenance treatment with adalimumab. Scand J Gastroenterol 2016;51:442-7.
33. Ferreiro Iglesias R, Barreiro de Acosta M, Lorenzo A, et al. Accuracy of consecutive fecal calprotectin measurements to predict relapse in inflammatory bowel disease patients under maintenance with anti-TNF therapy: a prospective longitudinal cohort study. J Clin Gatroenterol 2018;52:229-34.
34. Valenzuela JE, Pereñiguez Lopez A, Perez Fernandez V, et al. Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn’s disease. Rev Esp Enferm Dig 2016;108:394-400. DOI: 10.17235/reed.2016.4318/2016
Related articles

Letter

Broadening perspectives in the treatment of chronic pouchitis

DOI: 10.17235/reed.2024.10865/2024

Letter

Treatment with hyperbaric oxygen in a Crohn’s disease patient

DOI: 10.17235/reed.2024.10166/2023

Letter

Lung abscess in a non-compliant patient with Crohn’s disease

DOI: 10.17235/reed.2024.10140/2023

Letter

Coincidental oral lesions in Crohn’s disease

DOI: 10.17235/reed.2023.9992/2023

Letter

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Letter

Duodenal stenosis surgical treatment in Crohn’s disease

DOI: 10.17235/reed.2023.9521/2023

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Letter

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Letter

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Digestive Diseases Image

Peristomal cutaneous Crohn's disease by contiguity

DOI: 10.17235/reed.2022.8909/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

Mesalazine induced interstitial pneumonitis in the COVID era

DOI: 10.17235/reed.2022.8635/2021

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Review

New non-invasive biomarkers for colorectal cancer screening

DOI: 10.17235/reed.2020.7233/2020

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Letter

Sweet syndrome in severe ulcerative flare

DOI: 10.17235/reed.2020.6995/2020

Letter

Crohn’s disease in patients treated with etanercept

DOI: 10.17235/reed.2019.6554/2019

Letter to the Editor

Ulcerative colitis with gastric and duodenal involvement

DOI: 10.17235/reed.2017.4685/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Letter to the Editor

Adnexal localization of Crohn’s disease and recurrent massive ovary cysts

DOI: 10.17235/reed.2016.4301/2016

Case Report

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Case Report

Metastatic Crohn’s disease in pediatrics

DOI: 10.17235/reed.2016.3948/2015

Letter to the Editor

Crohn’s disease and Sweet’s syndrome: A debut together

DOI: 10.17235/reed.2015.3842/2015

Case Report

Ovarian involvement in Crohn´s disease: A rare complication

DOI: 10.17235/reed.2015.3764/2015

Citation tools
Ferreiro-Iglesias R, Barreiro-de Acosta M, López-Díaz J, Bastón Rey I, Domínguez-Muñoz J. Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study. 7683/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1839 visits.
This article has been downloaded 142 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 25/11/2020

Accepted: 14/01/2021

Online First: 25/01/2021

Published: 10/01/2022

Article revision time: 45 days

Article Online First time: 61 days

Article editing time: 411 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2024 y Creative Commons. The Spanish Journal of Gastroenterology